Xeris Biopharma (NASDAQ:XERS – Get Rating) is set to announce its earnings results before the market opens on Wednesday, May 11th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter.
Xeris Biopharma (NASDAQ:XERS – Get Rating) last issued its earnings results on Thursday, March 10th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.21). The firm had revenue of $21.43 million during the quarter, compared to analysts’ expectations of $20.72 million. Xeris Biopharma had a negative return on equity of 305.33% and a negative net margin of 248.68%. During the same period last year, the firm posted ($0.41) earnings per share. On average, analysts expect Xeris Biopharma to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
NASDAQ:XERS opened at $2.33 on Thursday. The company has a current ratio of 1.80, a quick ratio of 1.57 and a debt-to-equity ratio of 0.92. The company’s 50 day moving average price is $2.53 and its 200-day moving average price is $2.35. Xeris Biopharma has a 52 week low of $1.77 and a 52 week high of $4.98.
A number of hedge funds have recently made changes to their positions in the business. Cubist Systematic Strategies LLC raised its position in Xeris Biopharma by 1,677.0% in the fourth quarter. Cubist Systematic Strategies LLC now owns 311,797 shares of the company’s stock worth $914,000 after acquiring an additional 294,251 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Xeris Biopharma by 83.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 227,691 shares of the company’s stock worth $667,000 after purchasing an additional 103,507 shares in the last quarter. Morgan Stanley raised its holdings in Xeris Biopharma by 66.2% in the 3rd quarter. Morgan Stanley now owns 245,957 shares of the company’s stock worth $603,000 after purchasing an additional 97,992 shares during the period. Bank of America Corp DE lifted its position in Xeris Biopharma by 97.1% during the second quarter. Bank of America Corp DE now owns 54,115 shares of the company’s stock valued at $220,000 after purchasing an additional 26,666 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Xeris Biopharma by 44.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 69,872 shares of the company’s stock worth $204,000 after buying an additional 21,402 shares in the last quarter. 18.72% of the stock is owned by institutional investors and hedge funds.
Several brokerages have commented on XERS. Mizuho cut their target price on Xeris Biopharma from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, March 16th. Zacks Investment Research cut Xeris Biopharma from a “hold” rating to a “sell” rating in a research report on Thursday, January 20th. HC Wainwright reissued a “buy” rating and issued a $6.00 target price (down previously from $8.00) on shares of Xeris Biopharma in a research report on Friday, March 11th. Craig Hallum assumed coverage on shares of Xeris Biopharma in a report on Thursday, April 28th. They set a “buy” rating and a $6.50 price target on the stock. Finally, SVB Leerink decreased their price objective on shares of Xeris Biopharma from $8.00 to $6.00 and set an “outperform” rating for the company in a report on Wednesday, February 16th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $6.13.
Xeris Biopharma Company Profile (Get Rating)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
- Get a free copy of the StockNews.com research report on Xeris Biopharma (XERS)
- World Wresting Entertainment Stock is Hulking Up
- High-Yield Weyco Group Returns To Reasonable Levels
- MarketBeat Podcast: Alternative Investing Strategies Despite Market Volatility
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.